CY1120581T1 - Ενωσεις και μεθοδοι χρησης τους - Google Patents
Ενωσεις και μεθοδοι χρησης τουςInfo
- Publication number
- CY1120581T1 CY1120581T1 CY20181100864T CY181100864T CY1120581T1 CY 1120581 T1 CY1120581 T1 CY 1120581T1 CY 20181100864 T CY20181100864 T CY 20181100864T CY 181100864 T CY181100864 T CY 181100864T CY 1120581 T1 CY1120581 T1 CY 1120581T1
- Authority
- CY
- Cyprus
- Prior art keywords
- unions
- methods
- compounds
- glutaminase
- cancers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Παρέχονται ενώσεις του τύπου (I), που μπορούν να αναστέλλουν γλουταμινάση. Παρέχονται επίσης συνθέσεις που περιλαμβάνουν αυτές τις ενώσεις και χρήσεις ως αναστολείς γλουταμινάσης για θεραπευτική αγωγή καρκίνων με αυτές.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2012/085023 WO2014079011A1 (en) | 2012-11-22 | 2012-11-22 | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
PCT/CN2013/000294 WO2014079136A1 (en) | 2012-11-22 | 2013-03-15 | Compounds, pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof |
PCT/CN2013/001428 WO2014079150A1 (en) | 2012-11-22 | 2013-11-21 | Compounds and their methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120581T1 true CY1120581T1 (el) | 2019-07-10 |
Family
ID=50775393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100864T CY1120581T1 (el) | 2012-11-22 | 2018-08-17 | Ενωσεις και μεθοδοι χρησης τους |
Country Status (36)
Country | Link |
---|---|
US (2) | US10087172B2 (el) |
EP (2) | EP2922850B1 (el) |
JP (2) | JP6333277B2 (el) |
KR (1) | KR20150085079A (el) |
CN (2) | CN108727307A (el) |
AR (1) | AR093598A1 (el) |
AU (2) | AU2013347771B2 (el) |
BR (1) | BR112015011830A2 (el) |
CA (1) | CA2893510C (el) |
CL (1) | CL2015001392A1 (el) |
CR (1) | CR20150316A (el) |
CY (1) | CY1120581T1 (el) |
DK (1) | DK2922850T3 (el) |
EA (2) | EA030646B1 (el) |
EC (1) | ECSP15026557A (el) |
ES (1) | ES2690390T3 (el) |
HK (1) | HK1214593A1 (el) |
HR (1) | HRP20181628T1 (el) |
HU (1) | HUE040111T2 (el) |
IL (1) | IL238958B (el) |
LT (1) | LT2922850T (el) |
MX (1) | MX367389B (el) |
MY (1) | MY177344A (el) |
NZ (1) | NZ708382A (el) |
PE (1) | PE20151072A1 (el) |
PH (2) | PH12015501150B1 (el) |
PL (1) | PL2922850T3 (el) |
PT (1) | PT2922850T (el) |
RS (1) | RS57859B1 (el) |
SA (1) | SA515360469B1 (el) |
SG (2) | SG11201504049VA (el) |
SI (1) | SI2922850T1 (el) |
TR (1) | TR201812360T4 (el) |
TW (2) | TW201906825A (el) |
UA (1) | UA117360C2 (el) |
WO (3) | WO2014079011A1 (el) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
EP2920168B1 (en) | 2012-11-16 | 2021-07-21 | Calithera Biosciences, Inc. | Heterocyclic glutaminase inhibitors |
CN105263915B (zh) | 2012-11-21 | 2019-04-12 | 安吉奥斯医药品有限公司 | 谷氨酰胺酶抑制剂及使用方法 |
WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
US20150004134A1 (en) * | 2012-12-03 | 2015-01-01 | Calithera Biosciences, Inc. | Treatment of cancer with heterocyclic inhibitors of glutaminase |
ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
TW201932456A (zh) | 2013-01-15 | 2019-08-16 | 美商英塞特控股公司 | 適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物 |
AR097431A1 (es) | 2013-08-23 | 2016-03-16 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim |
KR20160100408A (ko) | 2014-01-06 | 2016-08-23 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 글루타미나제 저해제 |
EP3119199B1 (en) | 2014-03-21 | 2020-03-18 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
ES2759434T3 (es) | 2014-04-30 | 2020-05-11 | Pfizer | Derivados de diheterociclo unidos a cicloalquilo |
GB201409624D0 (en) | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
EP3677579A1 (en) | 2014-07-03 | 2020-07-08 | Board of Regents, The University of Texas System | Heterocyclic gls1 inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
WO2016014890A1 (en) * | 2014-07-24 | 2016-01-28 | Calithera Biosciences, Inc. | Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase |
EA037738B1 (ru) | 2014-08-07 | 2021-05-17 | Калитера Байосайенсиз, Инк. | Кристаллические формы ингибиторов глутаминазы |
US10245254B2 (en) | 2014-10-03 | 2019-04-02 | University of Pittsburgh—of the Commonwealth System of Higher Education | Glutaminase inhibitors |
CN107949387B (zh) | 2015-04-06 | 2021-08-13 | 卡利泰拉生物科技公司 | 用谷氨酰胺酶抑制剂治疗肺癌 |
WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
JP6895396B2 (ja) * | 2015-06-30 | 2021-06-30 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | 疾患を処置するためのgls1阻害薬 |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
EP3359150A4 (en) | 2015-10-05 | 2019-11-06 | Calithera Biosciences, Inc. | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGICAL AGENTS |
US10040789B2 (en) * | 2015-11-30 | 2018-08-07 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
CN109503570B (zh) * | 2015-12-18 | 2020-08-25 | 诺言医药科技(上海)有限公司 | 一种含有索拉非尼的药物组合物及其应用 |
US10150753B2 (en) | 2015-12-22 | 2018-12-11 | Board Of Regents, The University Of Texas System | Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide |
EP3503886A4 (en) * | 2016-08-25 | 2020-07-22 | Calithera Biosciences, Inc. | POLYTHERAPY INCLUDING GLUTAMINASE INHIBITORS |
US10195197B2 (en) | 2016-08-25 | 2019-02-05 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
RU2020112558A (ru) | 2017-10-18 | 2021-11-18 | Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем | Терапия на основе ингибитора глутаминазы |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
EP3876928B1 (en) | 2018-11-08 | 2024-10-23 | Merck Sharp & Dohme LLC | Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection |
US20220400732A1 (en) * | 2019-03-21 | 2022-12-22 | Cornell University | Anti-fructose therapy for colorectal and small intestine cancers |
CN110746416A (zh) * | 2019-09-05 | 2020-02-04 | 中国药科大学 | 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途 |
CN112898200A (zh) * | 2021-01-20 | 2021-06-04 | 都创(上海)医药科技股份有限公司 | 5-溴-6-甲氧基吡啶-2-羧酸酯的合成方法 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2037257A1 (en) | 1970-07-28 | 1972-02-03 | Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt | Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn |
US4070400A (en) | 1975-10-16 | 1978-01-24 | Merck & Co., Inc. | Diphenyl polyamides having a cyclohexylene moiety |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
SU1761672A1 (ru) * | 1990-05-22 | 1992-09-15 | Белгородский технологический институт строительных материалов им.И.А.Гришманова | Способ получени тонкодисперсного мела |
DE69425882T2 (de) | 1993-03-29 | 2001-01-11 | Basf Ag | 1-amino-3-phenoxy-propan-derivate als modulatoren bei multi-drug resistenz |
US5895748A (en) | 1996-11-27 | 1999-04-20 | Johnson; Keith R. | Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies |
EP1087951B9 (en) * | 1998-06-18 | 2006-09-13 | Bristol-Myers Squibb Company | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
WO2000052204A2 (en) | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
US20030054985A1 (en) | 2000-02-22 | 2003-03-20 | Stuart Aaronson | N-cadherin modulated migration, invasion, and metastasis |
US6974667B2 (en) | 2000-06-14 | 2005-12-13 | Gene Logic, Inc. | Gene expression profiles in liver cancer |
US6451828B1 (en) * | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
DE60200248T2 (de) | 2002-08-01 | 2005-01-27 | Mtm Laboratories Ag | Verfahren für Lösung-basierte Diagnose |
WO2006040569A1 (en) | 2004-10-14 | 2006-04-20 | Astex Therapeutics Limited | Thiophene amide compounds for use in the treatment or prophylaxis of cancers |
US20080182865A1 (en) | 2005-03-11 | 2008-07-31 | Witta Samir E | Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors |
DE602006016085D1 (de) | 2005-03-16 | 2010-09-23 | Genentech Inc | Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor |
US8716472B2 (en) | 2006-10-16 | 2014-05-06 | University Of Rochester | Tripodal cyclohexane derivatives and their use as carbohydrate receptors |
KR20100087330A (ko) | 2007-11-19 | 2010-08-04 | 제넨테크, 인크. | 종양 진행을 억제하기 위한 조성물 및 방법 |
WO2009111067A2 (en) | 2008-03-07 | 2009-09-11 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal -like tumor cells or their formation |
EP2399129B1 (en) | 2009-02-20 | 2015-11-25 | Michael P. Lisanti | A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm |
WO2010111504A2 (en) | 2009-03-25 | 2010-09-30 | Cornell University | Inhibition of glutaminase c |
US20120142028A1 (en) | 2009-04-17 | 2012-06-07 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
WO2011143160A2 (en) * | 2010-05-10 | 2011-11-17 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
EP3206034B1 (en) | 2010-06-23 | 2020-05-27 | University of Louisville Research Foundation, Inc. | Use of fatty acids in methods for detecting cancer |
US10064885B2 (en) | 2010-07-09 | 2018-09-04 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
UY33930A (es) | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
JP6031527B2 (ja) * | 2011-11-21 | 2016-11-24 | キャリセラ バイオサイエンシーズ, インコーポレイテッド | グルタミナーゼのヘテロ環式阻害剤 |
JP2015514062A (ja) | 2012-03-15 | 2015-05-18 | ザ リサーチ ファウンデーション フォー ザ ステイト ユニバーシティ オブ ニューヨーク | E−カドヘリンの細胞外ドメインの阻害剤を含む併用療法 |
CN105263915B (zh) | 2012-11-21 | 2019-04-12 | 安吉奥斯医药品有限公司 | 谷氨酰胺酶抑制剂及使用方法 |
US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
US20160008380A1 (en) | 2013-03-06 | 2016-01-14 | The Johns Hopkins University | Targeting glutamine metabolism in brain tumors |
KR20160100408A (ko) | 2014-01-06 | 2016-08-23 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 글루타미나제 저해제 |
EP3119199B1 (en) | 2014-03-21 | 2020-03-18 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
-
2012
- 2012-11-22 WO PCT/CN2012/085023 patent/WO2014079011A1/en active Application Filing
-
2013
- 2013-03-15 WO PCT/CN2013/000294 patent/WO2014079136A1/en active Application Filing
- 2013-11-21 PE PE2015000674A patent/PE20151072A1/es unknown
- 2013-11-21 TR TR2018/12360T patent/TR201812360T4/tr unknown
- 2013-11-21 US US14/646,634 patent/US10087172B2/en active Active
- 2013-11-21 DK DK13857585.7T patent/DK2922850T3/en active
- 2013-11-21 MY MYPI2015001355A patent/MY177344A/en unknown
- 2013-11-21 SI SI201331140T patent/SI2922850T1/sl unknown
- 2013-11-21 UA UAA201506066A patent/UA117360C2/uk unknown
- 2013-11-21 RS RS20181133A patent/RS57859B1/sr unknown
- 2013-11-21 ES ES13857585.7T patent/ES2690390T3/es active Active
- 2013-11-21 AU AU2013347771A patent/AU2013347771B2/en not_active Ceased
- 2013-11-21 CN CN201810824418.2A patent/CN108727307A/zh active Pending
- 2013-11-21 JP JP2015543242A patent/JP6333277B2/ja not_active Expired - Fee Related
- 2013-11-21 MX MX2015006493A patent/MX367389B/es active IP Right Grant
- 2013-11-21 EA EA201590987A patent/EA030646B1/ru not_active IP Right Cessation
- 2013-11-21 KR KR1020157016414A patent/KR20150085079A/ko not_active Application Discontinuation
- 2013-11-21 HU HUE13857585A patent/HUE040111T2/hu unknown
- 2013-11-21 EP EP13857585.7A patent/EP2922850B1/en active Active
- 2013-11-21 LT LTEP13857585.7T patent/LT2922850T/lt unknown
- 2013-11-21 NZ NZ708382A patent/NZ708382A/en unknown
- 2013-11-21 CA CA2893510A patent/CA2893510C/en active Active
- 2013-11-21 PT PT13857585T patent/PT2922850T/pt unknown
- 2013-11-21 EP EP18183580.2A patent/EP3456719A1/en not_active Withdrawn
- 2013-11-21 SG SG11201504049VA patent/SG11201504049VA/en unknown
- 2013-11-21 CN CN201380070365.5A patent/CN104936954B/zh not_active Expired - Fee Related
- 2013-11-21 SG SG10201609940RA patent/SG10201609940RA/en unknown
- 2013-11-21 WO PCT/CN2013/001428 patent/WO2014079150A1/en active Application Filing
- 2013-11-21 PL PL13857585T patent/PL2922850T3/pl unknown
- 2013-11-21 BR BR112015011830A patent/BR112015011830A2/pt not_active Application Discontinuation
- 2013-11-21 EA EA201890754A patent/EA201890754A1/ru unknown
- 2013-11-22 TW TW107111990A patent/TW201906825A/zh unknown
- 2013-11-22 TW TW102142566A patent/TWI629268B/zh not_active IP Right Cessation
- 2013-11-22 AR ARP130104322A patent/AR093598A1/es unknown
-
2015
- 2015-05-21 IL IL238958A patent/IL238958B/en not_active IP Right Cessation
- 2015-05-22 CL CL2015001392A patent/CL2015001392A1/es unknown
- 2015-05-22 PH PH12015501150A patent/PH12015501150B1/en unknown
- 2015-05-22 SA SA515360469A patent/SA515360469B1/ar unknown
- 2015-06-15 CR CR20150316A patent/CR20150316A/es unknown
- 2015-06-22 EC ECIEPI201526557A patent/ECSP15026557A/es unknown
-
2016
- 2016-03-04 HK HK16102486.9A patent/HK1214593A1/zh not_active IP Right Cessation
-
2017
- 2017-11-24 PH PH12017502141A patent/PH12017502141A1/en unknown
-
2018
- 2018-04-24 JP JP2018082754A patent/JP2018150316A/ja active Pending
- 2018-04-30 AU AU2018202954A patent/AU2018202954A1/en not_active Abandoned
- 2018-08-17 CY CY20181100864T patent/CY1120581T1/el unknown
- 2018-08-21 US US16/107,220 patent/US10689375B2/en not_active Expired - Fee Related
- 2018-10-10 HR HRP20181628TT patent/HRP20181628T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120581T1 (el) | Ενωσεις και μεθοδοι χρησης τους | |
CY1121129T1 (el) | Αναστολεις toy fgfr4 πυριμιδινης | |
CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
CR20180057A (es) | Nuevos compuestos biciclicos como inhibidores duales de atx/ca. | |
EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
TN2017000544A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
EA201791563A1 (ru) | Замещенные нуклеозидные производные, полезные в качестве агентов против рака | |
CR20180072A (es) | Nuevos compuestos biciclicos como inhibidores de atx | |
MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
CY1119042T1 (el) | Υποκατεστημενες ξανθινες και μεθοδοι χρησης αυτων | |
BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
EA201591961A1 (ru) | Ингибиторы акк и их применение | |
EA201492223A1 (ru) | Новые диазаспироциклоалканы и азаспироциклоалканы | |
PH12015502041B1 (en) | Heteroaryl compounds and uses thereof | |
EA201591960A1 (ru) | Ингибиторы акк и их применение | |
EA201591959A1 (ru) | Ингибиторы акк и их применение | |
MX2015008999A (es) | Inhibidores mk2 y usos de los mismos. | |
EA201591420A1 (ru) | Гетероарильные соединения и их применение | |
TR201813877T4 (tr) | Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler. | |
EA201390609A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
NZ721217A (en) | Biaryl inhibitors of bruton’s tyrosine kinase | |
CR20140229A (es) | Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona | |
CR20180143A (es) | Nuevos compuestos biciclicos como inhibidores duales de atx/ca | |
EA201591962A1 (ru) | Ингибиторы акк и их применение |